Amylyx Pharmaceuticals (AMLX) Competitors $9.95 +0.11 (+1.12%) Closing price 04:00 PM EasternExtended Trading$9.94 -0.01 (-0.15%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMLX vs. KYMR, AMRX, XENE, ARWR, VKTX, CRNX, RARE, MOR, NAMS, and HCMShould you be buying Amylyx Pharmaceuticals stock or one of its competitors? The main competitors of Amylyx Pharmaceuticals include Kymera Therapeutics (KYMR), AMNEAL PHARMACEUTICALS (AMRX), Xenon Pharmaceuticals (XENE), Arrowhead Pharmaceuticals (ARWR), Viking Therapeutics (VKTX), Crinetics Pharmaceuticals (CRNX), Ultragenyx Pharmaceutical (RARE), MorphoSys (MOR), NewAmsterdam Pharma (NAMS), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry. Amylyx Pharmaceuticals vs. Its Competitors Kymera Therapeutics AMNEAL PHARMACEUTICALS Xenon Pharmaceuticals Arrowhead Pharmaceuticals Viking Therapeutics Crinetics Pharmaceuticals Ultragenyx Pharmaceutical MorphoSys NewAmsterdam Pharma HUTCHMED Amylyx Pharmaceuticals (NASDAQ:AMLX) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability. Which has more volatility & risk, AMLX or KYMR? Amylyx Pharmaceuticals has a beta of -0.44, meaning that its share price is 144% less volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.17, meaning that its share price is 117% more volatile than the S&P 500. Is AMLX or KYMR more profitable? Amylyx Pharmaceuticals has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -616.03%. Kymera Therapeutics' return on equity of -31.60% beat Amylyx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Amylyx PharmaceuticalsN/A -82.48% -70.15% Kymera Therapeutics -616.03%-31.60%-27.12% Which has stronger valuation and earnings, AMLX or KYMR? Kymera Therapeutics has lower revenue, but higher earnings than Amylyx Pharmaceuticals. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmylyx Pharmaceuticals$87.37M10.15-$301.74M-$2.50-3.98Kymera Therapeutics$44.71M67.48-$223.86M-$3.47-12.16 Does the media favor AMLX or KYMR? In the previous week, Amylyx Pharmaceuticals had 5 more articles in the media than Kymera Therapeutics. MarketBeat recorded 13 mentions for Amylyx Pharmaceuticals and 8 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 1.14 beat Amylyx Pharmaceuticals' score of 0.96 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in AMLX or KYMR? 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 12.3% of Amylyx Pharmaceuticals shares are held by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend AMLX or KYMR? Amylyx Pharmaceuticals currently has a consensus target price of $12.25, suggesting a potential upside of 23.12%. Kymera Therapeutics has a consensus target price of $58.76, suggesting a potential upside of 39.25%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kymera Therapeutics is more favorable than Amylyx Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amylyx Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00Kymera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 15 Buy rating(s) 3 Strong Buy rating(s) 3.11 SummaryKymera Therapeutics beats Amylyx Pharmaceuticals on 11 of the 17 factors compared between the two stocks. Get Amylyx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMLX vs. The Competition Export to ExcelMetricAmylyx PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$887.24M$2.54B$5.76B$9.91BDividend YieldN/A48.51%6.66%4.49%P/E Ratio-3.9822.7183.0126.65Price / Sales10.15538.47503.03163.66Price / CashN/A26.3325.7028.92Price / Book5.296.7910.796.52Net Income-$301.74M$32.94M$3.29B$266.21M7 Day Performance5.63%0.48%0.02%-0.76%1 Month Performance25.00%6.61%7.06%3.83%1 Year Performance376.08%-0.50%50.09%24.39% Amylyx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMLXAmylyx Pharmaceuticals2.7364 of 5 stars$9.95+1.1%$12.25+23.1%+355.6%$887.24M$87.37M-3.98200News CoverageKYMRKymera Therapeutics3.4778 of 5 stars$41.82-5.2%$59.11+41.3%-6.5%$3.15B$47.07M0.00170News CoveragePositive NewsAMRXAMNEAL PHARMACEUTICALS3.0532 of 5 stars$9.28-3.2%$11.60+25.0%+12.4%$3.01B$2.79B14.318,100Positive NewsXENEXenon Pharmaceuticals2.6972 of 5 stars$38.14-1.8%$53.20+39.5%-3.3%$2.99B$9.43M0.00210News CoverageAnalyst ForecastOptions VolumeARWRArrowhead Pharmaceuticals4.2146 of 5 stars$20.71-2.9%$43.14+108.3%+21.3%$2.95B$3.55M-16.18400News CoverageAnalyst ForecastInsider TradeVKTXViking Therapeutics4.2763 of 5 stars$25.85-0.6%$86.92+236.3%-54.1%$2.92BN/A-16.9020Positive NewsAnalyst RevisionCRNXCrinetics Pharmaceuticals3.7079 of 5 stars$30.09-2.7%$68.86+128.8%-33.4%$2.91B$1.04M-7.32210News CoveragePositive NewsRAREUltragenyx Pharmaceutical4.5141 of 5 stars$29.27-1.7%$81.50+178.4%-43.4%$2.87B$560.23M-5.291,294News CoverageMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730NAMSNewAmsterdam Pharma3.8296 of 5 stars$24.70-1.2%$41.55+68.2%+56.4%$2.82B$45.56M0.004News CoverageHCMHUTCHMED2.0467 of 5 stars$15.93-1.1%$28.00+75.8%-12.4%$2.81B$630.20M0.001,811 Related Companies and Tools Related Companies Kymera Therapeutics Competitors AMNEAL PHARMACEUTICALS Competitors Xenon Pharmaceuticals Competitors Arrowhead Pharmaceuticals Competitors Viking Therapeutics Competitors Crinetics Pharmaceuticals Competitors Ultragenyx Pharmaceutical Competitors MorphoSys Competitors NewAmsterdam Pharma Competitors HUTCHMED Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMLX) was last updated on 9/4/2025 by MarketBeat.com Staff From Our Partners2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | Sponsored“Shadow Group” in Washington, DC Could Crash MarketNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amylyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
